Last updated: February 27, 2026
What is MYOVIEW?
MYOVIEW (generic: Iopamidol) is an injectable contrast agent used primarily in diagnostic imaging procedures such as computed tomography (CT) scans to enhance vascular and tissue visualization. It is a non-ionic, water-soluble iodinated contrast medium with a high safety profile in radiology.
What is the current formulation and excipient composition of MYOVIEW?
MYOVIEW’s formulation contains:
- Iopamidol as the active pharmaceutical ingredient (API)
- Excipients include:
- Water for injection as solvent
- Sodium chloride for isotonicity
- Sodium calcium edetate as a stabilizer
- pH adjusters such as sodium hydroxide or hydrochloric acid (precision varies by manufacturer)
The exact excipient composition is protected under confidential manufacturing data but generally includes stabilizers and buffering agents to maintain pH around 6.5–7.5.
What are the excipient considerations for MYOVIEW?
Excipients impact safety, stability, shelf-life, bioavailability, and regulatory compliance. For MYOVIEW specifically, key considerations include:
1. Safety and Tolerability
Excipients like sodium chloride are standard but must be carefully balanced to avoid hypernatremia or hypo-osmolarity. Edetate (EDTA) acts as a chelating agent, aiding stability but could pose toxicity risks if not used within recommended limits.
2. Stability and Shelf-life
The buffering agents and stabilizers prevent API degradation, maintaining high iodine potency over time. Compatibility with packaging materials such as rubber stoppers and pre-filled syringes influences formulation choices.
3. Patient-Friendly Formulation
Minimizing osmolarity and avoiding potential allergic responses to excipients enhances patient safety, especially for patients with renal impairment or allergies.
4. Manufacturing and Cost
Excipients should be readily available, affordable, and compatible with large-scale aseptic production. Stability in storage conditions affects distribution logistics.
What are alternative excipient strategies?
Innovations focus on enhancing safety and reducing adverse reactions:
- Osmolality reduction: Developing low-osmolar or iso-osmolar formulations, which may involve reducing sodium chloride content or using alternative buffering agents.
- Stabilizer optimization: Incorporating stronger chelating agents or antioxidants to prolong shelf-life.
- Biocompatible excipients: Using excipients with a lower risk of hypersensitivity or toxicity.
What is the market potential for excipient innovations?
Advances in excipient technology could provide MYOVIEW with a competitive edge:
Market drivers
- Increasing demand for high-quality contrast agents in imaging (expected market CAGR of 5.2% from 2021 to 2028 [2])
- Growing patient populations and procedural volume
- Emphasis on safety profiles with lower adverse event rates
Commercial opportunities
- Formulation differentiation: Offering low-osmolar or iso-osmolar versions to meet safety standards could command premium pricing.
- Partnerships and licensing: Collaborations with excipient developers could reduce R&D costs and accelerate regulatory approval.
- Global market expansion: Particularly in regions with rising healthcare infrastructure, emphasizing formulations with favorable safety profiles.
What regulatory considerations exist?
Excipients in contrast agents like MYOVIEW are subject to regulations from agencies including the FDA (US), EMA (Europe), and PMDA (Japan). Formulation changes require supplemental filings and stability data. Use of novel excipients or significant modifications to osmolarity, pH, or stabilizers necessitates extensive clinical testing.
How to align excipient strategy with commercialization?
Successful commercialization relies on:
- Prioritizing excipients with proven safety profiles
- Demonstrating formulation improvements through stability and clinical studies
- Securing regulatory approvals with comprehensive documentation
- Developing scalable manufacturing processes
- Marketing innovations as safety or efficacy enhancements
What are the competitive implications?
Developing excipient formulations that lower osmolality and adverse reaction risks can differentiate MYOVIEW. Competing contrast agents may already adopt such features, pressuring MYOVIEW to innovate or partner with excipient suppliers.
Key Takeaways
- MYOVIEW’s excipient strategy focuses on safety, stability, and manufacturability.
- Innovation in low-osmolar and biocompatible excipients offers growth opportunities.
- Regulatory pathways demand detailed stability and safety data for formulation changes.
- Market expansion depends on emphasizing safety improvements and cost competitiveness.
- Strategic partnerships with excipient specialists can accelerate development and regulatory approvals.
FAQs
1. Are there existing low-osmolar MYOVIEW formulations?
Current formulations are predominantly high-osmolar. R&D is exploring low- or iso-osmolar formulations to improve tolerability.
2. Can excipient changes extend shelf life?
Yes. Incorporating stabilizers and antioxidants can improve chemical stability, extending shelf-life from typical 2–3 years to beyond, pending regulatory approval.
3. What are the main regulatory hurdles for excipient innovation?
Regulatory agencies require comprehensive stability, safety, and efficacy data. Novel excipients or formulations must undergo clinical testing, increasing time and cost.
4. How does excipient choice influence patient safety?
Excipients like EDTA can cause toxicity in high doses, while buffers and stabilizers must not elicit allergic responses; formulating with proven, biocompatible excipients minimizes adverse reactions.
5. What commercial advantages come from excipient innovation?
New formulations with enhanced safety profiles can command premium pricing, facilitate market access, and support global expansion in regions with strict safety regulations.
References
[1] Smith, J., & Lee, R. (2021). Developments in contrast agent formulations: A review. Journal of Pharmaceutical Innovation, 16(4), 480–492.
[2] MarketsandMarkets. (2022). Contrast agents market by type, application, and region. Market Research Report.
